Daré Bioscience’s (DARE) Buy Rating Reiterated at HC Wainwright

Daré Bioscience (NASDAQ:DARE)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $12.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 236.61% from the stock’s current price.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Daré Bioscience in a report on Wednesday, August 14th.

Daré Bioscience Stock Performance

Shares of DARE stock opened at $3.57 on Friday. Daré Bioscience has a 52-week low of $3.05 and a 52-week high of $7.56. The stock has a market cap of $30.48 million, a price-to-earnings ratio of -3.18 and a beta of 1.34. The firm’s 50-day moving average is $3.56 and its 200-day moving average is $3.93.

Daré Bioscience (NASDAQ:DARE) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $2.09. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.60 million. Sell-side analysts predict that Daré Bioscience will post -0.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC raised its holdings in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the period. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 at the end of the most recent quarter. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.